These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 27199430)

  • 1. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.
    Lu CL; Murakowski DK; Bournazos S; Schoofs T; Sarkar D; Halper-Stromberg A; Horwitz JA; Nogueira L; Golijanin J; Gazumyan A; Ravetch JV; Caskey M; Chakraborty AK; Nussenzweig MC
    Science; 2016 May; 352(6288):1001-4. PubMed ID: 27199430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
    Kim KC; Choi BS; Kim KC; Park KH; Lee HJ; Cho YK; Kim SI; Kim SS; Oh YK; Kim YB
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):194-202. PubMed ID: 26564392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1.
    Matsushita S; Yoshimura K; Ramirez KP; Pisupati J; Murakami T;
    AIDS; 2015 Feb; 29(4):453-62. PubMed ID: 25630040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
    Klein F; Halper-Stromberg A; Horwitz JA; Gruell H; Scheid JF; Bournazos S; Mouquet H; Spatz LA; Diskin R; Abadir A; Zang T; Dorner M; Billerbeck E; Labitt RN; Gaebler C; Marcovecchio P; Incesu RB; Eisenreich TR; Bieniasz PD; Seaman MS; Bjorkman PJ; Ravetch JV; Ploss A; Nussenzweig MC
    Nature; 2012 Dec; 492(7427):118-22. PubMed ID: 23103874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.
    Joseph A; Zheng JH; Chen K; Dutta M; Chen C; Stiegler G; Kunert R; Follenzi A; Goldstein H
    J Virol; 2010 Jul; 84(13):6645-53. PubMed ID: 20410262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.
    Klein F; Nogueira L; Nishimura Y; Phad G; West AP; Halper-Stromberg A; Horwitz JA; Gazumyan A; Liu C; Eisenreich TR; Lehmann C; Fätkenheuer G; Williams C; Shingai M; Martin MA; Bjorkman PJ; Seaman MS; Zolla-Pazner S; Karlsson Hedestam GB; Nussenzweig MC
    J Exp Med; 2014 Nov; 211(12):2361-72. PubMed ID: 25385756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-retroviral antibody FcγR-mediated effector functions.
    Bournazos S; Ravetch JV
    Immunol Rev; 2017 Jan; 275(1):285-295. PubMed ID: 28133801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner.
    Tudor D; Bomsel M
    AIDS; 2011 Mar; 25(6):751-9. PubMed ID: 21330910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in HIV-1 antibody research using humanized mice.
    Gruell H; Klein F
    Curr Opin HIV AIDS; 2017 May; 12(3):285-293. PubMed ID: 28422792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.